TABR Capital Management LLC Invests $7.36 Million in Abbott Laboratories $ABT

TABR Capital Management LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 58,747 shares of the healthcare product maker’s stock, valued at approximately $7,360,000. Abbott Laboratories accounts for approximately 2.9% of TABR Capital Management LLC’s portfolio, making the stock its 7th largest position.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories during the second quarter worth about $32,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter worth approximately $33,000. Finally, Copia Wealth Management purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by company insiders.

Analyst Ratings Changes

ABT has been the subject of several recent research reports. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Citigroup lowered their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Finally, Piper Sandler dropped their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Trading Down 1.5%

Shares of NYSE ABT opened at $105.58 on Monday. The business has a 50 day simple moving average of $112.75 and a 200 day simple moving average of $122.97. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The stock has a market cap of $183.88 billion, a price-to-earnings ratio of 28.38, a PEG ratio of 1.68 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.